Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
The ACCOMPLISH trial concluded that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality. This pre-specified secondary analysis showed a reduction in progressive chronic kidney disease, defined as a doubling of serum creatinine concentration or development of end-stage renal disease, with an event rate of 2.0% in the benazepril/amlodipinie arm vs 3.7% in the benazepril/hydrochlorothiazide arm.
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
- Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
- Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis